Lightspeed Israel

Lightspeed Israel, established in 2006, is a venture capital firm based in Tel Aviv, Israel. It invests in seed, early, and later-stage companies across the information technology and TMT sectors. The firm focuses on supporting innovative Israeli startups, providing capital and strategic guidance to accelerate their growth. Lightspeed Israel typically invests between $2 million to $25 million per company, with a particular interest in enterprise, health, fintech, and consumer sectors. It manages multiple funds, including Lightspeed Venture Partners IX and Lightspeed India Partners I & II, to support its investment activities in Israel and India.

Shaurya Aggarwal

Partner

Vaibhav Agrawal

Venture Partner

James Alcorn

Partner

Saqib Awan

Partner

Moritz Baier-Lentz

Partner and Head of Gaming

Mercedes Bent

Partner

Luke Beseda

Partner

Akshay Bhushan

Partner

Taggart Bonham

Partner

Guru Chahal

Partner

Yoni Cheifetz

Partner

Yoni Cheifetz

Partner

Sun Daniel

Partner

Amish Desai

Partner

Sebastian Duesterhoeft

Partner

Barry Eggers

Co-Founder and Partner

Sam Eisler

Partner

James Ephrati

Partner

Faraz Fatemi

Partner, Consumer

Jack Fowler

Partner

Aaron Frank

Venture Partner

Merci Grace

Partner

Globin Guo

Executive Director

Gaurav Gupta

Partner

David Gussarsky

Partner

Herry Han

Co-Founder and Partner

Lisa Han

Partner

Rob Horton JD

COO

Galym Imanbayev

Partner

Galym Imanbayev MD

Partner

Nnamdi Iregbulem

Partner

Raviraj Jain

Partner

Arif Janmohamed

Partner

Julie Kainz

Partner

Francis Kao

Partner

Ansaf Kareem

Partner

Alex Kayyal

Partner

Dev Khare

Partner

Issac Kim

Partner

Will Kohler

Partner

Harsha Kumar

Associate Partner

Pinn Lawjindakul

Partner

Pachara Lawjindakul

Partner

Pachara Lawjindakul

Partner

Will Leas

Partner

Jeremy Liew

Partner

Connor Love

Partner

John Luongo

Venture Partner

Natalie Luu

Partner

Naveed Matinfar

Partner

Ravi Mhatre

Co-Founder and Partner

James Mi

Founding Partner

Andrew Moley

Operating Partner and CFO

Tal Morgenstern

Partner

Peter Nieh

Co-Founder and Partner, Enterprise

Justin Overdorff

Partner

Zac Pan

Associate Partner

Apoorva Pandhi

Associate

Krish Parikh

Partner of Business Services

Nicole Quinn

Partner

Adrian Nicholas Radu

Partner

Alexander Schmitt

Partner

Shan Shan

Partner

Justin Shen

Partner

Justin Shen

Partner

Shuvi Shrivastava

Partner

Ishaan Preet Singh

Investor

Ajay Sudan

Venture Partner

Sydney Sykes

Partner

Rahul Taneja

Partner

Alex Taussig

Partner

John Thompson

Venture Partner

Anoushka Vaswani

Partner

Jason Wang

Partner

Nathan Wang

Vice President

Nathan Wu

Partner, Growth

Mark Xu

Partner

Cici Yang

Vice President

Jerry Ye

Partner, Data Platform

Haowei Zhai

Vice President

Issac Zhang

Vice President

Ju Zhang

Executive Director

Gavin Zhu

Partner

Hu Peipei

Investment Manager

Past deals in Healthcare

Emversity

Seed Round in 2025
Emversity is an education organization focused on enhancing employability through vocational courses in the Allied Health Sciences. By developing an education technology platform, Emversity aims to bridge the gap between educational outcomes and industry requirements. The organization collaborates with industry experts to design programs that equip students with essential skills for success in the healthcare sector. Utilizing interactive learning methods, Emversity creates engaging and immersive educational experiences, empowering students with the knowledge and mindset necessary to thrive in a rapidly evolving job market.

Frontera Health

Seed Round in 2025
Frontera Health is changing autism care in underprivileged regions with AI-powered tools that assist physicians in evaluating and treating children with autism and related diseases.

Abridge

Series D in 2025
Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Eternal

Seed Round in 2025
With a mission to keep athletes active and thriving in their chosen sports for as long as possible, Eternal provides members with a holistic understanding of their health, fitness, and benchmarks for key markers of the aging process along with guidance from high-performance care teams to support every stage of an athlete’s journey.

Neko Health

Series B in 2025
Neko Health is a Swedish health-tech company focused on enhancing healthcare through prevention and early detection of diseases. It has developed innovative medical scanning technology that enables comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By leveraging sensor technology and artificial intelligence, Neko Health aims to reduce the prevalence of common diseases and their associated healthcare costs. The company provides doctors and clinicians with tools for flexible and cost-effective examinations, ultimately aiming to improve the quality of healthcare and promote proactive health management.

Senseera

Seed Round in 2025
Senseera focuses on creating liquid biopsy blood tests aimed at the early detection and monitoring of cancer and other human diseases. The company employs advanced techniques in molecular biology, sequencing, and computational analysis to extract epigenetic information from chromatin fragments found in circulating blood. This innovative approach transforms complex biological data into actionable clinical insights, enabling accurate and affordable health screenings for patients. Through its technology, Senseera aims to enhance the early identification of diseases, ultimately improving patient outcomes and healthcare delivery.

Anatomy Financial

Series A in 2024
Anatomy Financial specializes in streamlining financial operations for healthcare organizations that bill insurance. Their core offering is an automation platform that employs AI to convert insurance Explanation of Benefits (EOBs), reconcile financial data, and manage a modern healthcare lockbox. This suite of services aims to enhance efficiency and provide real-time financial insights, allowing healthcare providers to concentrate on delivering quality patient care.

Soda Health

Series B in 2024
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.

xAI

Series C in 2024
XAI is a technology company specializing in artificial intelligence. It creates and deploys AI solutions, primarily using machine learning, to enhance data analysis and decision-making processes. XAI caters to the finance, healthcare, and logistics sectors, aiming to improve accuracy and efficiency in these industries.

Alpha9 Theranostics

Series C in 2024
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Tennr

Series B in 2024
Tennr is a healthcare AI startup focused on optimizing operational efficiency in the healthcare sector by automating back-office tasks. The company has developed a workflow automation platform that tracks the lifecycle of patient referrals, allowing healthcare staff to reduce the time spent on manual workflows, information verification, and data entry. By replacing traditional faxing systems and enhancing communication processes, Tennr's technology facilitates timely care for patients and helps healthcare practices of all sizes achieve enterprise-quality automation.

Air Doctor

Series B in 2024
Air Doctor Ltd. operates an online marketplace that connects travelers with verified medical practitioners, facilitating access to healthcare services while abroad. Founded in 2016 and based in Motza Illit, Israel, the platform enables users to search for and book appointments with a variety of healthcare providers, including doctors, dentists, emergency clinics, pharmacies, and laboratories. It features profiles of practitioners along with patient reviews, allowing travelers to select professionals who meet their specific needs and speak their language. By streamlining the process of obtaining medical care in unfamiliar locations, Air Doctor enhances the travel experience for individuals seeking healthcare services.

Scorpion Therapeutics

Series C in 2024
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Pheon Therapeutics

Series B in 2024
Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Triomics

Series A in 2024
Triomics is a generative AI-powered platform focused on enhancing the efficiency of clinical trials, particularly in the field of oncology. The company aims to accelerate trial enrollment and improve healthcare operations by addressing operational inefficiencies in data collection and patient recruitment. Leveraging its advanced AI technology, which is trained to understand health records and medical terminology, Triomics facilitates a more streamlined approach to clinical research. Its platform supports pharmaceutical companies and contract research organizations in conducting rapid and cost-effective trials, ultimately advancing oncology research and care.

Abridge

Series C in 2024
Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Anatomy Financial

Seed Round in 2024
Anatomy Financial specializes in streamlining financial operations for healthcare organizations that bill insurance. Their core offering is an automation platform that employs AI to convert insurance Explanation of Benefits (EOBs), reconcile financial data, and manage a modern healthcare lockbox. This suite of services aims to enhance efficiency and provide real-time financial insights, allowing healthcare providers to concentrate on delivering quality patient care.

Emversity

Venture Round in 2023
Emversity is an education organization focused on enhancing employability through vocational courses in the Allied Health Sciences. By developing an education technology platform, Emversity aims to bridge the gap between educational outcomes and industry requirements. The organization collaborates with industry experts to design programs that equip students with essential skills for success in the healthcare sector. Utilizing interactive learning methods, Emversity creates engaging and immersive educational experiences, empowering students with the knowledge and mindset necessary to thrive in a rapidly evolving job market.

Ketryx

Series A in 2023
Ketryx, founded in 2021 and based in Cambridge, Massachusetts, specializes in software development tools aimed at the medical device sector. The company provides innovative solutions that integrate regulatory requirements and quality assurance processes, allowing teams to streamline their workflows. Ketryx's software connects all documentation, tests, and code into a single system that is traceable and navigable for FDA compliance. This approach enables regulated software teams to deliver safer and more reliable medical devices, ultimately fostering trust among patients globally.

Seismic Therapeutic

Series B in 2023
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Olema Oncology

Post in 2023
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Daybreak Health

Series B in 2023
Daybreak Health Inc. offers online counseling services specifically designed for teenagers, addressing issues such as achievement pressure, stress, social isolation, self-esteem, anxiety, and depression. Founded in 2019 and based in San Francisco, California, the company utilizes a mobile app to connect teens with specialized therapists who provide individual counseling and group sessions. Additionally, Daybreak Health offers wellbeing tools to help stabilize mental fitness among young people. The platform aims to facilitate quick access to mental health support, enabling teens and their parents to maintain a positive state of mind.

Berry Health

Pre Seed Round in 2023
Berry Health is a consumer health startup dedicated to improving lives by addressing under-served and stigmatized medical conditions. The company specializes in remote diagnosis and treatment for chronic health issues through online private medical consultations. Berry Health provides prescription medications and nationwide delivery, empowering patients to take control of their health. The services offered cover a wide range of conditions, including dermatology, mental health, sexual health, hair loss, and more, benefiting both men and women. By focusing on enhancing patient agency, Berry Health aims to promote better health outcomes, reduce inflammation and pain, optimize immunity, and improve brain health.

Aledade

Series F in 2023
Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

HealthPlix

Series C in 2023
HealthPlix is a pioneering digital health company in India that offers an AI-powered electronic medical record (EMR) platform designed to enhance healthcare delivery. The platform supports over 10,000 doctors across more than 370 cities, facilitating the treatment of over 22 million patients in various specialties. HealthPlix's technology provides clinical decision support at the point of care, particularly focusing on chronic diseases such as diabetes. The EMR system allows for personalized consultations based on individual patient histories and supports prescription generation in multiple languages, thus helping doctors transition from traditional paper-based methods to a more efficient digital approach.

Fathom

Series B in 2022
Fathom Health, founded in 2016 and based in San Francisco, California, provides artificial intelligence solutions aimed at streamlining the medical reimbursement process. The company has developed a coding automation platform that expedites medical coding practices by automatically reviewing incoming charts. In addition to this technology, Fathom offers full-service coding solutions and real-time comprehensive audits, allowing healthcare providers to enhance operational efficiency through automation. By leveraging AI, Fathom enables medical operators to optimize their coding processes, ultimately improving their business outcomes.

Soda Health

Series A in 2022
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.

Theranica

Series C in 2022
Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

WonderMind

Seed Round in 2022
WonderMind is a mental fitness ecosystem dedicated to democratizing and destigmatizing mental health on a global scale. Founded by Selena Gomez, Mandy Teefey, and Daniella Pierson, the company focuses on providing accessible and affordable mental wellness solutions. Through its platform, WonderMind offers customized peer-to-peer support, engaging daily content, and consumer packaged goods designed to prioritize mental fitness. The company's mission is to empower individuals by enhancing their understanding of mental health, encouraging personal growth, and improving overall well-being.

Ancora Biotech

Series A in 2022
Ancora Biotech is a biotechnology company dedicated to the development of antibody biotherapeutics aimed at treating life-threatening diseases. The company specializes in clinical development support for conditions such as B cell cancers, inflammatory and metabolic disorders, and chronic hepatitis B infections. By focusing on these areas, Ancora Biotech aims to provide healthcare professionals with effective treatment options to improve patient outcomes in various critical health situations.

Ultima Genomics

Venture Round in 2022
Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Air Doctor

Series B in 2022
Air Doctor Ltd. operates an online marketplace that connects travelers with verified medical practitioners, facilitating access to healthcare services while abroad. Founded in 2016 and based in Motza Illit, Israel, the platform enables users to search for and book appointments with a variety of healthcare providers, including doctors, dentists, emergency clinics, pharmacies, and laboratories. It features profiles of practitioners along with patient reviews, allowing travelers to select professionals who meet their specific needs and speak their language. By streamlining the process of obtaining medical care in unfamiliar locations, Air Doctor enhances the travel experience for individuals seeking healthcare services.

Zeera

Series B in 2022
Zeera is a mental healthcare company founded in 2019 by Ariela Safira, based in New York. The company focuses on providing a digital platform and in-person experiences aimed at enhancing mental wellness through a member-centered therapy model that is both affordable and effective. Zeera offers a monthly membership that includes on-demand, therapist-created tools and resources designed to assist users in managing experiences such as burnout. The platform emphasizes empathy and design, enabling individuals to access research-based therapy tools that encourage reflection and actionable steps for mental well-being. In addition to its mental health services, Zeera also caters to tech enthusiasts with accessories and gadgets compatible with Apple products, and embraces the cultural richness of Indian cuisine through authentic recipes and dining experiences for vegan and vegetarian customers.

NyquistAI

Seed Round in 2022
NyquistAI is focused on providing a comprehensive platform for accessing and analyzing life science data. Utilizing advanced machine learning technology, NyquistAI combines unstructured data from global clinical trials and real-world sources to deliver valuable insights for healthcare professionals. The platform aims to enhance research capabilities and inform business strategies by offering up-to-date and credible information that spans the entire innovation lifecycle in the medical technology sector. With customizable solutions, NyquistAI enables users to efficiently compile and interpret crucial data, thereby supporting informed decision-making and fostering innovative opportunities in the life sciences field.

Daybreak Health

Series A in 2022
Daybreak Health Inc. offers online counseling services specifically designed for teenagers, addressing issues such as achievement pressure, stress, social isolation, self-esteem, anxiety, and depression. Founded in 2019 and based in San Francisco, California, the company utilizes a mobile app to connect teens with specialized therapists who provide individual counseling and group sessions. Additionally, Daybreak Health offers wellbeing tools to help stabilize mental fitness among young people. The platform aims to facilitate quick access to mental health support, enabling teens and their parents to maintain a positive state of mind.

MDClone

Series C in 2022
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Seismic Therapeutic

Series A in 2022
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Curve Health

Series A in 2022
Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, predictive analytics, and smart billing. Founded in 2020 and based in New York, the platform facilitates remote care for patients in skilled nursing facilities, at home, and in emergency situations, significantly reducing the need for patient transfers to emergency departments. By streamlining communication and operations between healthcare providers and post-acute facilities, Curve Health improves care quality and patient outcomes while optimizing resource allocation. The platform also accelerates reimbursement processes and automates documentation, making it a comprehensive solution for modern healthcare challenges in senior care.

Mayd

Series A in 2022
MAYD Group is a startup focused on providing rapid medication delivery services. The company operates a platform that enables customers to receive pharmacy products directly at their doorstep in just minutes. By partnering with local pharmacies, MAYD ensures that users can conveniently access a variety of medical supplies online while receiving competent advice. This service aims to meet customers' healthcare needs promptly and efficiently.

Wheel

Series C in 2022
Wheel, Inc. is a digital health company based in Austin, Texas, that operates a tech-enabled marketplace connecting healthcare companies with clinicians. Founded in 2018, the company focuses on telehealth services, providing a platform that allows healthcare organizations to easily scale their virtual care offerings. Wheel's platform leverages machine learning algorithms to streamline the process for companies seeking to develop virtual care services under their own brand. By facilitating access to a nationwide network of clinicians, Wheel enhances opportunities for healthcare professionals while delivering quality digital healthcare solutions. Formerly known as Enzyme Health, Inc., the company rebranded to Wheel, Inc. in January 2020.

ThoughtSpot

Series F in 2021
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.

HilleVax

Venture Round in 2021
HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

NeuralGalaxy

Series A in 2021
Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.

Soda Health

Seed Round in 2021
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.

Nym

Venture Round in 2021
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, automates revenue cycle management by interpreting clinical language in patient charts and accurately assigning medical charge codes, reducing operational expenses, improving payment cycles, and enhancing audit readiness. Nym's solution identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. The company also has a research and development center in Tel Aviv-Yafo, Israel.

3T Biosciences

Series A in 2021
3T Biosciences, Inc. is an immunotherapy company established in 2017 and based in Menlo Park, California. The company focuses on developing innovative treatments for cancer and other T-cell-mediated diseases by utilizing synthetic biology and machine learning technologies. Its approach involves discovering novel targets for drug development, which aims to enhance the effectiveness of cancer therapies. Through its research and development efforts, 3T Biosciences is committed to providing healthcare professionals with advanced treatment options for patients facing cancer-related illnesses.

Shanghai LinkedCare Information Technology

Series D in 2021
Shanghai LinkedCare Information Technology Co., Ltd. specializes in developing software solutions for dental clinics and medical beauty institutions. Founded in 2015 and based in Shanghai, the company offers a range of products designed to enhance operational efficiency and management standards. Its dental cloud management software includes features such as electronic signatures, member management, treatment planning, clinic analysis, and inventory management. Additionally, LinkedCare provides medical beauty cloud management solutions, which encompass marketing tools, appointment scheduling, and cashier systems. The company's integrated platform aims to fully automate the operations of consumer medical enterprises, facilitating a comprehensive health management process that increases revenue, reduces risks, lowers costs, and improves overall efficiency.

Abata Therapeutics

Series A in 2021
Abata Therapeutics is dedicated to developing innovative cell therapies aimed at treating autoimmune and inflammatory diseases, particularly progressive multiple sclerosis and type 1 diabetes. The company focuses on harnessing regulatory T cells (Tregs) to restore balance in the immune system, engineering these cells to specifically target disease-related antigens for precise treatment. This approach allows for effective disease management without the need for systemic immune suppression, enabling patients to maintain stable and active tissue residency. Founded by experts in immunology and cell therapy, Abata has garnered substantial investment from venture capital and biopharmaceutical firms, with the mission of translating advanced scientific research into meaningful therapies that enhance the quality of life for individuals affected by chronic autoimmune conditions.

Wheel

Series B in 2021
Wheel, Inc. is a digital health company based in Austin, Texas, that operates a tech-enabled marketplace connecting healthcare companies with clinicians. Founded in 2018, the company focuses on telehealth services, providing a platform that allows healthcare organizations to easily scale their virtual care offerings. Wheel's platform leverages machine learning algorithms to streamline the process for companies seeking to develop virtual care services under their own brand. By facilitating access to a nationwide network of clinicians, Wheel enhances opportunities for healthcare professionals while delivering quality digital healthcare solutions. Formerly known as Enzyme Health, Inc., the company rebranded to Wheel, Inc. in January 2020.

Parting Stone

Seed Round in 2021
Parting Stone is a company that specializes in transforming human and animal cremated remains into solidified remains, offering families an alternative to traditional ashes. Founded in 2019 and headquartered in Santa Fe, New Mexico, the company utilizes innovative technology to convert the entire amount of remains into a collection of stone-like solids. This process allows families to create a meaningful connection with their loved ones while providing a unique way to memorialize them. Parting Stone aims to provide a comforting option for families navigating the complexities of loss and memorialization.

Zeera

Series A in 2021
Zeera is a mental healthcare company founded in 2019 by Ariela Safira, based in New York. The company focuses on providing a digital platform and in-person experiences aimed at enhancing mental wellness through a member-centered therapy model that is both affordable and effective. Zeera offers a monthly membership that includes on-demand, therapist-created tools and resources designed to assist users in managing experiences such as burnout. The platform emphasizes empathy and design, enabling individuals to access research-based therapy tools that encourage reflection and actionable steps for mental well-being. In addition to its mental health services, Zeera also caters to tech enthusiasts with accessories and gadgets compatible with Apple products, and embraces the cultural richness of Indian cuisine through authentic recipes and dining experiences for vegan and vegetarian customers.

HealthPlix

Series B in 2021
HealthPlix is a pioneering digital health company in India that offers an AI-powered electronic medical record (EMR) platform designed to enhance healthcare delivery. The platform supports over 10,000 doctors across more than 370 cities, facilitating the treatment of over 22 million patients in various specialties. HealthPlix's technology provides clinical decision support at the point of care, particularly focusing on chronic diseases such as diabetes. The EMR system allows for personalized consultations based on individual patient histories and supports prescription generation in multiple languages, thus helping doctors transition from traditional paper-based methods to a more efficient digital approach.

MingMed

Series A in 2021
MingMed is a Chinese pharmaceutical company focused on independent drug research and development, with a diverse product pipeline that includes ophthalmic drugs, small molecule immune drugs, and cell therapies utilizing gene editing. The company's offerings extend to recombinant protein botulinum toxin, tumor immune drugs, and immunotherapy for pets. MingMed is dedicated to producing innovative solutions across various fields, including ophthalmology, medical aesthetics, and veterinary medicine, with several of its promising drug candidates having reached the clinical stage. The company's commitment to developing First-in-Class innovative drugs positions it competitively in the global pharmaceutical market.

Bluepha

Series B in 2021
Bluepha is a company that specializes in synthetic biotechnology, integrating bioengineering and data science to create innovative bio-based products. It focuses on the research and development of microbial manufacturing and material innovation, applying synthetic biology to optimize cells for diverse applications, including energy and pharmaceuticals. Bluepha aims to deliver value across various industries such as consumer goods, healthcare, specialty chemicals, agriculture, and electronics. By leveraging bio-engineering techniques, the company enables clients to assemble products from engineered cell materials, advancing the field of bio-manufacturing.

Radicle Science

Pre Seed Round in 2021
Radicle Science is an AI-driven health technology company that offers a unique Proof-as-a-Service solution aimed at validating the efficacy of non-pharmaceutical products. By developing a virtual direct-to-consumer clinical trials platform, Radicle Science enables brands in the natural medicine sector, including those in the cannabinoid industry, to differentiate themselves through evidence-based insights. The company's proprietary data analytics platform utilizes digital health technologies, big data, and crowdsourcing to gather objective health outcome data. This approach allows clients to understand how customers experience their products both in real-world scenarios and controlled trial environments, thereby enhancing product credibility and market differentiation.

Freespira

Series D in 2020
Freespira is a pioneer in behavioral healthcare, offering evidence-based, at-home solutions that are drug-free. The company’s flagship product, Freespira®, is the only FDA-cleared digital therapeutic specifically designed to reduce or eliminate symptoms of panic attacks, panic disorder, and post-traumatic stress disorder (PTSD) within 28 days. This innovative treatment program utilizes a small breathing sensor connected to a tablet, complemented by weekly coaching support to help patients normalize respiratory irregularities and manage stress effectively. By focusing on non-pharmaceutical interventions, Freespira aims to transform the approach to treating anxiety-related conditions.

Calm

Series C in 2020
Calm is a San Francisco-based company established in 2012, specializing in digital wellness products aimed at enhancing mental fitness and alleviating common mental health issues like anxiety, depression, insomnia, and stress. The company's flagship product is its meditation and relaxation app, which offers original audio content, stories, and programs to help users manage stress and improve overall well-being. Calm has been recognized for its impact, being named Apple's 2017 iPhone App of the Year and Google Play's Editors' Choice in 2018.

Curve Health

Seed Round in 2020
Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, predictive analytics, and smart billing. Founded in 2020 and based in New York, the platform facilitates remote care for patients in skilled nursing facilities, at home, and in emergency situations, significantly reducing the need for patient transfers to emergency departments. By streamlining communication and operations between healthcare providers and post-acute facilities, Curve Health improves care quality and patient outcomes while optimizing resource allocation. The platform also accelerates reimbursement processes and automates documentation, making it a comprehensive solution for modern healthcare challenges in senior care.

Nym

Series A in 2020
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, automates revenue cycle management by interpreting clinical language in patient charts and accurately assigning medical charge codes, reducing operational expenses, improving payment cycles, and enhancing audit readiness. Nym's solution identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. The company also has a research and development center in Tel Aviv-Yafo, Israel.

Lark

Series C in 2020
Lark is a developer of a virtual chronic disease prevention and management platform that offers personalized support and counseling to users. Utilizing advanced artificial intelligence alongside human coaches and connected devices, Lark provides real-time, 24/7 assistance, helping individuals make healthier choices and manage chronic conditions effectively. The company has established CDC-recognized programs, including its Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program, which collectively serve 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in 11 peer-reviewed journals and analyst reports. Founded in 2011 by Julia Hu and Jeff Zira, Lark is headquartered in Mountain View, California.

Orca Bio

Series D in 2020
Orca Bio is a clinical-stage cell therapy company focused on providing curative treatments for patients suffering from malignant and autoimmune diseases. The company has developed proprietary technologies aimed at replacing diseased blood and immune systems with healthy cells. Orca Bio specializes in the research and development of innovative cell therapies that enhance the effectiveness of bone marrow transplants, creating a life-saving platform for various medical conditions. With a team of leading experts and technologists, Orca Bio is committed to advancing its pipeline of therapies to improve patient outcomes and transform healthcare practices.

Bluepha

Series A in 2020
Bluepha is a company that specializes in synthetic biotechnology, integrating bioengineering and data science to create innovative bio-based products. It focuses on the research and development of microbial manufacturing and material innovation, applying synthetic biology to optimize cells for diverse applications, including energy and pharmaceuticals. Bluepha aims to deliver value across various industries such as consumer goods, healthcare, specialty chemicals, agriculture, and electronics. By leveraging bio-engineering techniques, the company enables clients to assemble products from engineered cell materials, advancing the field of bio-manufacturing.

NeuralGalaxy

Seed Round in 2020
Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.

Hevo Data

Seed Round in 2019
Hevo Data Inc. is a software-as-a-service company specializing in data integration services. Founded in 2016 and headquartered in San Francisco, California, with an additional office in Bengaluru, India, Hevo offers a platform that allows users to connect and transfer data from diverse sources, including databases, cloud storage, cloud applications, and streaming services. The platform also facilitates the analysis of data across various formats and silos. Hevo Data serves a wide range of industries, including fintech, hospitality, e-commerce, healthcare, and edtech, among others. The company's automated data pipeline solutions are designed to simplify and enhance data management for organizations.

Calm

Secondary Market in 2019
Calm is a San Francisco-based company established in 2012, specializing in digital wellness products aimed at enhancing mental fitness and alleviating common mental health issues like anxiety, depression, insomnia, and stress. The company's flagship product is its meditation and relaxation app, which offers original audio content, stories, and programs to help users manage stress and improve overall well-being. Calm has been recognized for its impact, being named Apple's 2017 iPhone App of the Year and Google Play's Editors' Choice in 2018.

MDClone

Series B in 2019
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

ThoughtSpot

Series E in 2019
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.

Calm

Series B in 2019
Calm is a San Francisco-based company established in 2012, specializing in digital wellness products aimed at enhancing mental fitness and alleviating common mental health issues like anxiety, depression, insomnia, and stress. The company's flagship product is its meditation and relaxation app, which offers original audio content, stories, and programs to help users manage stress and improve overall well-being. Calm has been recognized for its impact, being named Apple's 2017 iPhone App of the Year and Google Play's Editors' Choice in 2018.

Theranica

Series B in 2019
Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

SleepSpace

Venture Round in 2018
SleepSpace is a pioneering technology company that has developed the first Sleep Operating System, aimed at enhancing sleep quality through innovative integration of sound, vibration, and light in the smart bedroom. Its platform accurately measures sleep patterns, offering superior insights compared to traditional wearables, and is compatible with various popular devices such as Apple Watch and Oura. SleepSpace's proprietary nearable sleep sensing technology transforms smartphones into smart beds, providing valuable data for coaches and clinicians to deliver tailored sleep interventions. The platform not only facilitates clinical sleep programs but also combines objective device data with users' subjective sleep experiences. Additionally, SleepSpace has successfully partnered with leading mattress brands, hotels, and corporate wellness initiatives, while securing over $3.5 million in grants from the NIH to support its mission of improving sleep health.

TeneoBio

Venture Round in 2018
TeneoBio, Inc. is a biotechnology company focused on developing human heavy chain antibodies, known as UniAbs, for therapeutic applications in cancer, autoimmunity, and infectious diseases. Since its founding in 2009 and headquartered in Menlo Park, California, the company has advanced several products targeting conditions such as multiple myeloma, prostate cancer, immune disorders, and AIDS. TeneoBio utilizes its proprietary antibody discovery platform, which includes genetically engineered animals and advanced technologies like next-generation sequencing and bioinformatics. This platform enables the rapid identification of unique binding molecules, facilitating the development of bispecific and trispecific antibodies as well as immune checkpoint inhibitors. The company aims to enhance patients' immune responses to overcome various diseases and disorders.

Innovaccer

Series B in 2018
Innovaccer Inc. is a technology company that specializes in developing analytical and data science applications primarily for the healthcare sector, along with industries such as financial services, manufacturing, and retail. The company offers a comprehensive Healthcare Intelligence Cloud that aggregates and analyzes patient data from various sources, including electronic health records and medical devices, to provide actionable insights. Its suite of solutions includes Datashop, which encompasses tools for patient care management, risk assessment in financial markets, and healthcare trend analysis. Innovaccer's platforms facilitate improved clinical workflows, care coordination, and operational efficiency by integrating functionalities for population health management and billing processes. Founded in 2012 and headquartered in Noida, India, with an office in Palo Alto, California, Innovaccer serves a diverse clientele, including academic institutions and governmental organizations, both domestically and internationally.

ThoughtSpot

Series D in 2018
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.

MDClone

Series A in 2018
MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Arctic Wolf

Series B in 2018
Arctic Wolf Networks, Inc., established in 2012 and headquartered in Eden Prairie, Minnesota, specializes in providing comprehensive cybersecurity solutions to businesses. The company offers a suite of services including Managed Detection and Response, Managed Risk, and Managed Cloud Monitoring, delivered through its unique concierge security team model. This approach extends the capabilities of clients' internal teams, offering tailored threat detection, response, and ongoing risk management. Arctic Wolf's platform employs continuous vulnerability assessment, real-time monitoring, and machine learning to provide actionable insights and alerts, enabling businesses to proactively combat cyber threats without needing to invest in their own security operations center. The company serves a diverse range of industries, with a particular focus on financial services, healthcare, legal enterprises, and other mid-to-large sized organizations.

Forty Seven

Series B in 2017
Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

Cairns Health

Seed Round in 2017
Cairns Health is a digital care companion and enablement platform for senior living and home care. The company's digital care plan enablement solution integrates intelligent ambient sensing (radar), artificial intelligence (AI) and large language models (LLM's) to streamline caregiver-patient interactions, boost engagement, and empower patients with a better understanding of their care plans, leading to timely interventions that improve care while reducing overall care delivery costs.

ThoughtSpot

Series C in 2017
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.

Theranica

Series A in 2017
Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

Guardant Health

Series E in 2017
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Collectly

Pre Seed Round in 2017
Collectly, Inc. is a company that specializes in debt recovery software, primarily aimed at healthcare organizations. Founded in 2016 and based in Walnut, California, Collectly offers a platform that automates the collection of overdue payments from business customers. The software tracks outstanding invoices, analyzes potential overdue payments, and communicates with customers through automated emails and chat. It enhances the patient financial experience by streamlining revenue cycle operations, facilitating online payments, and enabling customizable payment plans. By leveraging data-driven insights and artificial intelligence, Collectly assists medical practices and hospitals in improving patient collections and reducing accounts receivable, ultimately simplifying the billing process for both providers and patients.

Comprehend Systems

Series C in 2017
Comprehend Systems, Inc. is a provider of cloud-based continuous quality solutions for clinical operations, founded in 2010 and headquartered in Redwood City, California. The company offers a suite of clinical intelligence applications designed to enhance the speed, safety, and quality of clinical trials. These solutions support clinical operations executives, data managers, and medical monitors by delivering actionable insights for portfolio monitoring, CRO oversight, risk management, and collaboration across various teams and sites. Comprehend's tools aim to streamline the clinical trial process, improving overall performance and risk assessment throughout the research lifecycle. As of August 2019, Comprehend operates as a subsidiary of Saama Technologies, Inc.

PlushCare

Series A in 2016
PlushCare, Inc. is a telemedicine provider based in San Francisco, California, established in 2013. The company offers a virtual primary care platform that connects patients with board-certified doctors through video chat. Users can schedule online appointments to receive diagnoses, treatment plans, and prescriptions for a range of medical issues, including chronic conditions and urgent care needs. With a focus on delivering a friendly and personalized healthcare experience, PlushCare has served over 100,000 patients, receiving high ratings for customer satisfaction. The platform also includes services for mental health treatment and has developed at-home testing for Coronavirus.

Innovaccer

Series A in 2016
Innovaccer Inc. is a technology company that specializes in developing analytical and data science applications primarily for the healthcare sector, along with industries such as financial services, manufacturing, and retail. The company offers a comprehensive Healthcare Intelligence Cloud that aggregates and analyzes patient data from various sources, including electronic health records and medical devices, to provide actionable insights. Its suite of solutions includes Datashop, which encompasses tools for patient care management, risk assessment in financial markets, and healthcare trend analysis. Innovaccer's platforms facilitate improved clinical workflows, care coordination, and operational efficiency by integrating functionalities for population health management and billing processes. Founded in 2012 and headquartered in Noida, India, with an office in Palo Alto, California, Innovaccer serves a diverse clientele, including academic institutions and governmental organizations, both domestically and internationally.

ThoughtSpot

Series C in 2016
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.

Evariant

Series C in 2016
Evariant, Inc. is a healthcare technology company based in Farmington, Connecticut, founded in 2008. It provides a comprehensive platform designed to assist healthcare organizations in optimizing patient acquisition and retention while improving engagement with both patients and physicians. Evariant's solutions include tools for understanding patient demographics, managing marketing campaigns, and fostering two-way communication. The company offers a range of services, including analytics for tracking physician referral patterns, relationship management platforms for collaboration with healthcare providers, and recruitment tools for enhancing physician outreach. Additionally, Evariant provides digital media services, project management consulting, and a marketplace for healthcare analytics products. With a strong client base that includes over 1,000 hospitals nationwide, Evariant aims to drive growth and improve healthcare delivery by leveraging actionable intelligence and advanced data analytics.

Zhangshang Yaodian

Series B in 2016
Zhangshang Yaodian is a pharmacy app that provides safe medication services.

Forty Seven

Series A in 2016
Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

Guardant Health

Series D in 2016
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Evariant

Series C in 2015
Evariant, Inc. is a healthcare technology company based in Farmington, Connecticut, founded in 2008. It provides a comprehensive platform designed to assist healthcare organizations in optimizing patient acquisition and retention while improving engagement with both patients and physicians. Evariant's solutions include tools for understanding patient demographics, managing marketing campaigns, and fostering two-way communication. The company offers a range of services, including analytics for tracking physician referral patterns, relationship management platforms for collaboration with healthcare providers, and recruitment tools for enhancing physician outreach. Additionally, Evariant provides digital media services, project management consulting, and a marketplace for healthcare analytics products. With a strong client base that includes over 1,000 hospitals nationwide, Evariant aims to drive growth and improve healthcare delivery by leveraging actionable intelligence and advanced data analytics.

NuMedii

Series A in 2015
NuMedii, Inc. is a biotechnology company focused on discovering and developing drug candidates by leveraging life sciences big data technology. Founded in 2008 and headquartered in San Mateo, California, NuMedii utilizes an extensive array of biological, pharmacological, and clinical data to identify new therapeutic options and indications for existing drugs. The company aims to de-risk drug candidates by analyzing complex biological networks related to diseases, thereby addressing unmet medical needs. NuMedii collaborates with pharmaceutical companies for the clinical development and commercialization of its drug candidates, supported by strategic alliances with partners such as Aptalis Pharma and Three Lakes Partners, LLC.

Xingren Doctor

Series B in 2015
In China, almost every doctor must face overloaded with work. The number of patients they received a day or even a week,the number of foreign doctors will be reception. In addition to China's large population of natural conditions, the unity of the health care system, pattern, so difficult and tense doctor-patient relationship and other issues remain unresolved.

Tencent Trusted Doctors

Series B in 2015
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Guardant Health

Series C in 2015
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Kuai Heatlh Direct

Angel Round in 2014
Kuai Health Direct is an on-demand food delivery service that enables users to purchase specific nutritious foods directly through its website. The company employs a self-built logistics model to facilitate fast delivery, potentially within one hour. Additionally, Kuai Health Direct provides a mobile commerce platform designed to integrate food providers and retail channels, enhancing their online-to-offline operations. This approach aims to streamline the food purchasing experience while promoting healthier eating options.

Comprehend Systems

Series B in 2014
Comprehend Systems, Inc. is a provider of cloud-based continuous quality solutions for clinical operations, founded in 2010 and headquartered in Redwood City, California. The company offers a suite of clinical intelligence applications designed to enhance the speed, safety, and quality of clinical trials. These solutions support clinical operations executives, data managers, and medical monitors by delivering actionable insights for portfolio monitoring, CRO oversight, risk management, and collaboration across various teams and sites. Comprehend's tools aim to streamline the clinical trial process, improving overall performance and risk assessment throughout the research lifecycle. As of August 2019, Comprehend operates as a subsidiary of Saama Technologies, Inc.

Tencent Trusted Doctors

Series A in 2014
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Acupera

Series A in 2014
Acupera Inc. is a digital health company that specializes in population health and care coordination solutions for healthcare provider organizations. Founded in 2011 and based in San Francisco, California, Acupera offers a platform that connects diverse care teams to create patient-centric care plans. Its services include population health advisory services, an integration engine that aggregates data from electronic health records, labs, claims, and remote monitoring, as well as tools for population analytics, reporting, and referral network management. These solutions are designed to help health systems, hospitals, physicians, and value-based contracts manage patient populations effectively while achieving operational and performance objectives.

Cognito

Seed Round in 2014
Cognito specializes in intelligent identity verification solutions, offering a platform that enables businesses to verify customer identities for compliance and anti-fraud purposes. Its identity verification APIs assess various data points, including name, date of birth, address, and identification numbers, ensuring compliance with Know Your Customer (KYC) regulations. The company serves diverse sectors such as crowdfunding, virtual currency, healthcare, and on-demand services. Founded in 2013 and based in Palo Alto, California, Cognito was previously known as BlockScore, Inc. before rebranding in 2014. The platform is designed to streamline the verification process, addressing common challenges faced by developers in integrating identity verification within their applications.

ThoughtSpot

Series B in 2014
ThoughtSpot, Inc. is a provider of search-driven analytics designed for enterprises, enabling users to easily search and analyze data, generate instant charts, build reports, and create dashboards. Founded in 2012 and headquartered in Sunnyvale, California, ThoughtSpot serves various sectors including retail, healthcare, financial services, and manufacturing. The company's platform leverages a natural language search interface, allowing users to obtain actionable insights quickly and efficiently. It connects seamlessly with on-premise, cloud, and big data sources, centralizing data management and facilitating intelligent decision-making. Additionally, ThoughtSpot offers low-code integration solutions for developers, enhancing analytics capabilities within existing products and services. With a focus on empowering users to explore data, ThoughtSpot aims to drive growth and improve business outcomes across organizations. The company has expanded its presence globally with locations in multiple countries, including the United Kingdom, Germany, France, India, and Japan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.